Dirozalkib - Xuanzhu Biopharmaceutical
Alternative Names: Dexitinib - Xuanzhu Biopharmaceutical; Xuan Fei Ning; XZP-3621Latest Information Update: 09 Jul 2026
At a glance
- Originator Xuanzhu Biopharmaceutical
- Class 2 ring heterocyclic compounds; Amines; Aniline compounds; Antineoplastics; Chlorinated hydrocarbons; Piperidines; Pyrimidines; Small molecules; Sulfones
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Non-small cell lung cancer
Most Recent Events
- 22 Apr 2026 Efficacy and adverse event data from the phase II trial for Non-small cell lung cancer presented at the 117th Annual Meeting of the American Association for Cancer Research 2026 (AACR-2026)
- 17 Apr 2026 Efficacy and adverse event data from the phase III trial for Non-small cell lung cancer presented at the 117th Annual Meeting of the American Association for Cancer Research 2026 (AACR-2026)
- 26 Aug 2025 Chemical structure information added.